ArticleJHLT open2025
Peak steps to measure ''capacity for activity'': Actigraphy in the ADAPT registry with oral treprostinil.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03045029 (ADAPT - A Patient Registry of the Real-world Use of Orenitram®), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Who cites it
3 citing papers in PubMed.
- Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial.Annals of the American Thoracic Society · 2026Trial
- Remote exercise assessment in pulmonary hypertension.Current opinion in pulmonary medicine · 2026Review
- Longitudinal Remote 6-Minute Walk Distance and Cardiac Effort Using Wearable Sensors in Pulmonary Hypertension.Pulmonary circulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pulmonary arterial hypertension (PAH) patients have low activity time. Actigraphy provides an objective quantification of movement outside of clinic visits (home, work, social activities). Summary actigraphy measures (total daily steps or activity time) have not been shown to increase after adding therapies in patients with PAH. We developed a novel treatment responsive metric, Peak Steps, to measure the 'capacity for movement' in patients with PAH. Using data from the ADAPT registry (NCT03045029), we calculated Peak Steps and used summary actigraphy measurements and correlated it with six-minute walk distance (6MWD) and emPHasis-10 quality of life scores. After exposure to oral treprostinil, we observed a significant increase in Peak Steps, but no change in total daily steps or activity time. Peak Steps correlated strongly with 6MWD and emPHasis-10 scores. We propose that Peak Steps is a more sensitive marker of treatment response than traditional actigraphy parameters, which can have large behavioral influences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.